ArticleJournal of neuro-oncology2026
Risk factors and long-term outcomes in smart syndrome: a multicenter study.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: SMART syndrome mimicking Todd's paralysis after meningioma irradiation.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
purposeSMART (Stroke-like migraine attacks after radiotherapy) is a rare, late-onset complication of cranial radiotherapy (RT) consisting in episodes of neurological dysfunction associated with migraine-type headaches. We aimed to identify factors associated with the severity of first SMART episode, recurrence and overall survival.
methodsWe retrospectively reviewed patients diagnosed with modified SMART criteria (2010-2023) from nine Spanish hospitals. Demographic, clinical, neuroimaging, treatment and outcome data were analyzed.
resultsThirty-one patients (48% females) were included. Median age at SMART diagnosis was 49 (16-80) years. Median latency after RT was 13 (1-36) years. Most patients had primary brain tumors (84%). Nearly half received focal RT (45%), 32 % whole-brain RT and 23% received both. Severe episodes occurred in 61% (n = 19): 13 met a single severity criterion (intensive care unit admission, n = 1; status epilepticus (SE), n = 1; long-lasting episode, n = 11), and six met multiple criteria. Male sex (OR = 6.5, p = 0.024) and longer latency between RT and SMART onset (OR = 1.15, p = 0.016) were independently associated with severe presentation. Recurrent episodes occurred in 45%. The presence of ictal cortical FLAIR hyperintensity (OR = 0.08, p < 0.032) and longer episode duration (OR = 0.92, p < 0.035) were linked to lower recurrence. SE and known tumor prognostic factors predicted poorer survival.
conclusionsThis study highlights the heterogeneous long-term outcome of SMART syndrome. Severe initial episodes are common, especially in males and those with longer RT latency. Cortical FLAIR hyperintensity and prolonged first episodes are associated with reduced recurrence risk, while SE has a negative impact on survival.
Indexed as
Identifiers
42257762What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.